Showing 3991-4000 of 5646 results for "".
- Study: Reduced Oxygen Transport to the Retina Contributing to Damage to the Fine Blood Vessels Causes Diabetic Retinopathyhttps://modernod.com/news/study-reduced-oxygen-transport-to-the-retina-owing-to-damage-to-the-fine-blood-vessels-causes-diabetic-retinopathy/2481492/Researchers in Austria have now found evidence for a previously suspected connection: reduced oxygen transport to the retina contributes to damage to the fine blood vessels, causing diabetic retinopathy. A common complication of diabetes, this retinal damage can ultimately lead to blind
- International Sports Vision Association Announces Leadership Appointments OF NEW EXECUTIVE AND ADVISORY BOARD OFFICERShttps://modernod.com/news/international-sports-vision-association-announces-leadership-appointments-of-new-executive-and-advisory-board-officers/2481491/The International Sports Vision Association (ISVA) announced the appointments of its new Executive and Advisory Board members, effective April 1, 2023. Executive Board Alireza Somji, OD assumes the position of President, succeeding Charles Shidlofsky, OD, FCOV
- The American Diabetes Association and Genentech Partner to Increase Equitable Access to Eye Health Carehttps://modernod.com/news/the-american-diabetes-association-and-genentech-partner-to-increase-equitable-access-to-eye-health-care/2481482/The American Diabetes Association (ADA) and Genentech announced a new partnership as part of the ADA’s Health Equity Now work to tackle access to screening and treatment for eye diseases that affect the diabetes communit
- Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congresshttps://modernod.com/news/nicox-announces-presentations-of-additional-ncx-470-data-at-the-upcoming-world-glaucoma-congress/2481481/Nicox SA announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress (WGC), which will be held from June 28 to July 1, 2023 in Rome, Italy. Details of the presentations: Poster Title: Effects of NCX 470, a Nitric Oxide (NO)-Donati
- Researchers: Night Vision Tests in AMD Precisely Localize Disease Mechanismshttps://modernod.com/news/researchers-night-vision-tests-in-amd-precisely-localize-disease-mechanisms/2481479/Researchers at the University of Alabama at Birmingham discovered that night vision tests at a specific location in the retina will be suitable for assessing treatments and preventions for age-related macular degeneration (AMD), according to a university
- Aviceda Submits Investigational New Drug Application for AVD-104 for the Treatment of GA Associated with AMDhttps://modernod.com/news/aviceda-submits-investigational-new-drug-application-for-avd-104-for-the-treatment-of-ga-associated-with-amd/2481477/Aviceda Therapeutics announced that it has submitted an investigational new drug (IND) application to the FDA. The IND supports the use of its lead intravitreal ocular asset, AVD-104 (a novel glycan-coated nanoparticle), for the treatment of GA secondary to AMD. Aviceda previously announced
- Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Diseasehttps://modernod.com/news/kuria-therapeutics-completes-fda-pre-ind-consultation-for-topical-nrf2-activator-for-corneal-endothelial-disease/2481475/Kuria Therapeutics has announced it has completed a pre-investigational new drug (IND) interaction with the FDA and received positive feedback on its development program for KTX-1161 for corneal endothelial disease. KTX-1161 is a topical ophthalmic solution formulation of SCO-
- BioCareSD and AllyRetina GPO Partner to Help Retina Providers Improve Patient Care and Increase Efficiencyhttps://modernod.com/news/biocaresd-and-allyretina-gpo-partnership-to-help-retina-providers-improve-patient-care-and-increase-efficiency/2481473/BioCareSD announced its partnership with AllyRetina. Debuting at the American Society of Retina Specialists (ASRS) 24th Annual Business of Retina conference this week, AllyRetina will serve its GPO members through its physician leadership, a seasoned management team, and innovative tools and
- HCP Cureblindness Acquires SightLife Internationalhttps://modernod.com/news/hcp-cureblindness-acquires-sightlife-international/2481471/HCP Cureblindness announced it is acquiring SightLife International, the global division of the SightLife organization, with full integration of systems, programs, and brand to come over the next 12 months. Financial terms of the deal were not disclosed. F
- LumiThera Announces Sustained Vision Improvement for 24 Months in Dry AMD Subjects from US LIGHTSITE III Trialhttps://modernod.com/news/lumithera-announces-sustained-vision-improvement-for-24-months-in-dry-amd-subjects-from-us-lightsite-iii-clinical-trial-data/2481469/LumiThera announced 24-month data from its LIGHTSITE III multicenter clinical trial which demonstrated sustained vision improvement in dry age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked